← board
ENGNW
distress 5/10 · elevated risk$0.36-84%today-89% from 52w high
Lead: BCG-unresponsive NMIBC with Cis
Revenue
pre-revenue
Liquidity
$285M
Runway
2.6 yrs
Shares 1y
+31%
Price & events
-89.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-83.9%
1D
+12.0%
1W
-83.9%
1M
-83.9%
3M
—
6M
—
1Y
—
2Y
—
5Y
-89.2%
All
Overview
- Market Cap
- $24.12M
- Volume
- 4.00K
- 52 Week Range
- $0.31 – $3.33
- Total Shares
- 66.99M
- Float Shares
- 22.49M
- RVOL
- 18.46x
- Beta
- -0.28
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- mid '26regulatory submissionFiled (NDA/BLA)detalimogene voraplasmid · BLA filing for detalimogene voraplasmid in NMIBCSEC 8-K
- fourth quarter of 2024trial initiationsecondaryPhase 2detalimogene voraplasmid · Enrollment start for LEGEND cohorts 2a, 2b, and 3SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — BCG-unresponsive NMIBC with Cis
Recent news
- 2026-07-17enGene Highlights Progress of Lead Bladder Cancer Therapy - TipRanks
- 2026-07-17enGene Holdings appoints new chairman to guide growth - TipRanks
- 2026-07-16enGene appoints Michael Heffernan as board chairman By Investing.com - Investing.com Australia
- 2026-07-16enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones - BioSpace
- 2026-07-16enGene appoints Michael Heffernan as board chairman By Investing.com - Investing.com Australia
- 2026-07-16enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones - FinancialContent
- 2026-06-15enGene Therapeutics Inc. (ENGNW) Q2 2026 Quarterly Report: Financial Highlights, Risk Factors, and Forward-Looking Statements – Minichart - Minichart
- 2026-05-09enGene Stock Plunges As LEGEND Trial Downgrades Mount - timothysykes.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.